BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.

 Key Statistics


Email: info@iderapharma.com
Ownership: Public

Web Site: Idera Pharmaceuticals, Inc.
Employees:
Symbol: IDRA
 









 Company News
Idera Pharmaceuticals, Inc. (IDRA) Announces Several Key Additions To Management Team 12/15/2014 8:10:25 AM
Idera Pharmaceuticals, Inc. (IDRA) Presents Data Supporting IMO-8400 As Novel Therapy For Genetically Defined Forms Of B-Cell Lymphoma At Annual American Society of Hematology Meeting 12/9/2014 10:59:22 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Appointment Of Robert A. Doody Jr. As Vice President Of Investor Relations And Corporate Communications 12/5/2014 9:55:17 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent And Systemic Anti-Tumor Activity In Preclinical Models 12/3/2014 11:15:41 AM
Idera Pharmaceuticals, Inc. (IDRA) Names Vincent J. Milano CEO 12/2/2014 7:54:32 AM
Idera Pharmaceuticals, Inc. (IDRA) To Present At The Stifel 2014 Healthcare Conference 11/13/2014 10:39:22 AM
Idera Pharmaceuticals, Inc. (IDRA) And Parent Project Muscular Dystrophy Announce Collaboration To Advance New Treatment Approach For Duchenne Muscular Dystrophy 11/7/2014 10:41:28 AM
Idera Pharmaceuticals, Inc. (IDRA) Reports Third Quarter Financial Results And Announces Expansion Of Rare Disease Development Portfolio 11/7/2014 10:16:34 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Upcoming Presentations Of Data From Oncology Programs At Key Scientific Meetings 11/6/2014 1:09:46 PM
Idera Pharmaceuticals, Inc. (IDRA) To Announce Third Quarter 2014 Financial Results And Corporate Update On November 7, 2014 10/30/2014 8:06:47 AM
12345678910...